Active Surveillance for Early-Stage Prostate Cancer

The presentation by Dr. Peter Carroll is a valuable contribution to the discourse on prostate cancer management, offering a data-driven perspective on active surveillance. Drawing from two decades of UCSF data, Carroll provides robust evidence supporting the safety and efficacy of active surveillance for low-risk and selected intermediate-risk prostate cancer. The talk is well-structured, systematically addressing key factors that influence surveillance decisions, including MRI, PSA density, cancer volume, histologic subtype, and genomic testing. Carroll’s emphasis on the importance of histologic subtype is particularly noteworthy, as it is often underappreciated in clinical practice. He cites specific statistics, such as a 2% metastasis risk and <1% prostate cancer-specific mortality at 10 years, which are compelling and reassuring. The argumentation is solid, with logical progression from risk stratification to outcomes and predictors of progression. However, the presentation is not without limitations. While Carroll references UCSF data, he does not provide specific citations or references to peer-reviewed publications, which would strengthen the credibility of his claims. Additionally, some statements, such as the correlation between unfavorable histologic subtype and gene expression profiles, are mentioned without detailed evidence. The talk also touches on controversial topics, such as the role of ethnicity and the debate over whether grade 1 disease should be called cancer, but these are not explored in depth. The adéquation between title and content is excellent, as the talk focuses precisely on active surveillance for early-stage prostate cancer. Overall, the presentation is scientifically rigorous, clinically relevant, and offers valuable insights for both clinicians and patients. The lack of formal references is a minor drawback, but the expertise of the speaker and the institutional data lend credibility. The talk would benefit from more explicit citations to allow viewers to verify the data independently.

The title accurately reflects the content, which focuses on active surveillance for early-stage prostate cancer, including criteria, outcomes, and innovations.

8/10

Presentation by a leading urologic oncologist at UCSF, based on two decades of institutional data. The talk is data-driven, with clear statistics on outcomes, and emphasizes evidence-based decision-making. However, it is a conference presentation, not a peer-reviewed publication, and some claims are not fully referenced in the video.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction: Prostate cancer as a spectrum, treatment decisions based on cancer, patient health, and preferences.
• 02:00UCSF data: shift from surgery for low-risk to selective surgery for high-risk disease over 20 years.
• 04:00Key factors for surveillance: MRI, age, health, family history, germline mutations, PSA density, cancer volume, grade, histologic subtype.
• 06:0010-year outcomes: 60% reclassification, 17% major reclassification, 2% metastasis, 98% overall survival, &lt;1% prostate cancer-specific mortality.
• 08:00Predictors of progression: younger age, low PSA density, low volume, favorable histologic subtype, negative MRI, low PI-RADS, favorable genomics, negative biopsy.
• 10:00Discussion of grade 2 cancers: many do well on surveillance, especially with low volume and favorable histologic subtype.
• 12:00Innovations: AI-assisted pathology to predict outcomes from biopsy images, democratizing oncology.

• UCTV — Platform hosting the video and related content.
• UCTV Health & Medicine — Collection of health and medicine videos from University of California.
• Prostate Cancer Patient Conference — Conference where this talk was recorded.

• Prostate Cancer: Active Surveillance - American Cancer Society — Supports the safety of active surveillance for low-risk prostate cancer.
• Active Surveillance for Prostate Cancer - National Cancer Institute — Provides general information on active surveillance as a management option.

• Prostate Cancer: Active Surveillance - American Cancer Society — While generally supportive, some guidelines may have different criteria for selecting patients for active surveillance, particularly for intermediate-risk disease.